Project 5 involves a multilevel molecular genetic, cytochemical and functional approach focused on understanding the role of neurotrophic factors in the NGF and TGFbeta family in the central nervous system. In particular, we will evaluate the involvement of these factors in the maintenance of cholinergic projections and for other functions in hippocampus and cortex cerebri, as well as the possibilities to use neurotrophic factors in the NGF and TGFbeta family to reverse age-related neurodegenerative disorders. Experiments in project 5 can be subdivided as follows: (1) Cloning of new members of the TGFbeta family, emphasis on GDNF-related molecules and GDNF receptors. Accumulating evidence suggests that GDNF is an important neurotrophic factor for dopaminergic and cholinergic neurons. It is important to clone and characterize GDNF receptors, and it is very likely that GDNF, being a distant member of the TGFbeta family constitutes the first found member of a new TGFbeta sub- family. (2) Characterization of neurotrophic factors using the in vitro ganglia bioassay system; Known members of the TGFbeta family and, in particular any new GDNF-related molecules discovered in project 5 or by other scientists will be characterized in the highly specific 5-ganglia in vitro bioassay system with predictive value for in vivo effects. (3) Mapping the cellular distribution of neurotrophic factor: Using primarily in situ hybridization, but also immunohistochemistry, we will map the precise cellular localization of GDNF and any GDNF-related factors and/or GDNF receptors in the adult CNS. Additionally factors and receptors in the NGF family will be mapped in further detail. (4) Transient and permanent neurotrophic factor expression systems: GDNF, related molecules and receptors as well as NGF will be expressed by transient systems to manufacture the proteins and by permanent expression systems to be used as sources of trophic factor in collaboration with project 4. (5) Distribution and behavioral effects of neurotrophic factors injected into adult and aged normal animals: This part will evaluate in detail the spatial and temporal distribution of neurotrophic factors injected into the CSF or into brain tissue. This information is crucial for interpretation of behavioral studies which will be carried out after acute and chronic injections of neurotrophins, GDNF and novel GDNF-related factors. (6) High-resolution magnetic resonance imaging: Using new dedicated equipment enabling imaging of magnetic resonance spectroscopic information, we will monitor circulatory and metabolic changes in the brain over time in animals following intracranial injections of neurotrophic factors. (7) Functional effects of novel neurotrophic factors: Novel GDNF-related neurotrophic factors found by project 5 or by other scientists will be made using recombinant technology and used for functional studies in collaboration with project 4, (8) Studies of human post-mortem brain tissue: Postmortem brain tissue from patients with Alzheimer's disease and age-matched controls will be studied using in situ hybridization technology proven to work in such tissue to search for any possible changes in the expression of GDNF, related molecules or receptors, or neurotrophins and their receptors in Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG004418-17
Application #
6311455
Study Section
Project Start
2000-05-01
Project End
2001-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
17
Fiscal Year
2000
Total Cost
$147,576
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Bickford, Paula C; Flowers, Antwoine; Grimmig, Bethany (2017) Aging leads to altered microglial function that reduces brain resiliency increasing vulnerability to neurodegenerative diseases. Exp Gerontol 94:4-8
Grimmig, Bethany; Kim, Seol-Hee; Nash, Kevin et al. (2017) Neuroprotective mechanisms of astaxanthin: a potential therapeutic role in preserving cognitive function in age and neurodegeneration. Geroscience 39:19-32
Tajiri, Naoki; Acosta, Sandra A; Shahaduzzaman, Md et al. (2014) Intravenous transplants of human adipose-derived stem cell protect the brain from traumatic brain injury-induced neurodegeneration and motor and cognitive impairments: cell graft biodistribution and soluble factors in young and aged rats. J Neurosci 34:313-26
Lee, Daniel C; Ruiz, Claudia R; Lebson, Lori et al. (2013) Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiol Aging 34:1610-20
Lee, D C; Rizer, J; Hunt, J B et al. (2013) Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology. Neuropathol Appl Neurobiol 39:69-85
Ross, Jaime M; Stewart, James B; Hagström, Erik et al. (2013) Germline mitochondrial DNA mutations aggravate ageing and can impair brain development. Nature 501:412-5
Shahaduzzaman, Md; Golden, Jason E; Green, Suzanne et al. (2013) A single administration of human umbilical cord blood T cells produces long-lasting effects in the aging hippocampus. Age (Dordr) 35:2071-87
Olson, Linus; Faulkner, Stuart; Lundströmer, Karin et al. (2013) Comparison of three hypothermic target temperatures for the treatment of hypoxic ischemia: mRNA level responses of eight genes in the piglet brain. Transl Stroke Res 4:248-57
Morganti, Josh M; Nash, Kevin R; Grimmig, Bethany A et al. (2012) The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease. J Neurosci 32:14592-601
Li, Qingyou; Lebson, Lori; Lee, Daniel C et al. (2012) Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load. J Neuroimmune Pharmacol 7:202-14

Showing the most recent 10 out of 317 publications